



Sunitinib Newbury approved by the Danish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Sunitinib Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals in Sweden and Norway are expected to follow upon finalized national reviews.

Sunitinib is a prescription drug used to treat specific types of cancer in the kidney (advanced RCC), pancreas (pNET) and stomach (GIST). Sunitinib works by stopping tumour cells multiplying rapidly and also by reducing the growth of new blood vessels in the tumour. Sunitinib has its effect by targeting receptor tyrosine kinases (RTKs) which are receptors on the surface of cells which are important for the development and progression of some types of cancer.

“We are pleased to expand our portfolio of oncology products with the registration of Sunitinib Newbury in Denmark. The approval of Sunitinib Newbury is the first registration obtained in Denmark – and we now have obtained registration of various products in all three Scandinavian markets.”, says Lars Minor - CEO, Newbury Pharmaceuticals.

Sunitinib Newbury is part of the oncology pipeline with 11 products expected to be registered in the years ahead. The launch of Sunitinib Newbury will be subject to individual timelines per country and subject to timing and acceptance of tenders.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release
29 March 2022 16:30:00 CEST



Attachments

[Sunitinib Newbury approved by the Danish Health Authorities](#)